

Final Two Adjunct Biomarkers Technically Validated

- **Successful technical validation of final two adjunct biomarkers;**
- **Delivers five technically validated biomarkers, underpinning the core intellectual property obtained from CSIRO;**
- **Prototype ColoSTAT[®] test-kit being finalised; and**
- **Commencing transfer to high volume manufacturer.**

29 September 2020, Melbourne: Rhythm Biosciences Limited (ASX: RHY) is pleased to confirm that antibodies for the final two adjunct biomarkers for the ColoSTAT[®] test have been successfully technically validated, stabilised and proven to be reproducible.

All five technically validated biomarkers (one lead, four adjunct) are intended to be combined in a single test that will form the final ColoSTAT[®] test-kit. The completion of the technical validation of all current biomarkers is a critical milestone achievement and provides increased confidence as the development program progresses on the path towards commercialisation.

With the core antibody technology technically validated, the Company is focusing on completing the next phase in the development program which includes refining the ColoSTAT[®] test-kit algorithm, via further analytical cancerous and healthy blood sample testing, transferring the core technology to a third party (high volume) manufacturer and completing further verification testing to finalise the first prototype test-kit.

"It is a very exciting time for the Company. We are buoyed with the significant progress we have made with the core technology. A considerable amount of work has gone into selecting, screening, optimising and now technically validating the antibodies for the biomarkers that we expect will make up the final ColoSTAT[®] test-kit" Rhythm CEO, Glenn Gilbert said.

Rhythm's ColoSTAT[®] test-kit, is expected to be a global, low-cost, simple blood test for the detection of colorectal cancer aimed at mass market screening.

With the authority of the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower overall cost to public health administrations. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be equipment agnostic and easily used by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.